Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database
JCO Precision Oncology · 2024
DOI: 10.1200/po.23.00390 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Prashanth Ashok Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Upstate Cancer Center, Upstate University Hospital, Syracuse, NY. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Results from the TAILORx trial revealed that the use of adjuvant chemotherapy along with endocrine therapy had no survival advantage in patients with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2–negative (HER2–), node-negative (N0) breast cancer (BC) with an intermediate (11-25) 21-gene recurrence score (RS) in the overall population. However, in patients under age 50 years, adjuvant chemotherapy demonstrated a progression-free survival benefit when the RS ranged from 16-25. We studied this cohort with the population-based national database. METHODS The 2010-2018 National Cancer Database was used to include patients with BC age 18-50 years, N0, M0, RS 16-25, ER+/progesterone receptor±, and HER2–. Patients were divided into two groups on the basis of adjuvant chemotherapy use, and the survival between them was compared. RESULTS Adjuvant chemotherapy use was noted in 4,808/15,792 (30.45%) patients. Median RS was 18 and 21 in patients without and with adjuvant chemotherapy, respectively. Factors associated with adjuvant chemotherapy use were higher T stage, poor and moderately differentiated tumors, age
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Upstate Cancer Center, Upstate University Hospital, Syracuse, NY.
- Department of Public Health and Preventive Medicine, Upstate University Hospital, Syracuse, NY.
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.
ORCID-Profile: Prashanth Ashok Kumar, Abirami Sivapiragasam
Zitieren
APA
Ashok Kumar, P., Wang, D., Huang, D., & Sivapiragasam, A. (2024). Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database. JCO Precision Oncology. https://doi.org/10.1200/po.23.00390
Vancouver
Ashok Kumar P, Wang D, Huang D, Sivapiragasam A. Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database. JCO Precision Oncology. 2024. doi:10.1200/po.23.00390
BibTeX
@article{AshokKumar2024,
author = {Ashok Kumar, Prashanth and Wang, Dongliang and Huang, Danning and Sivapiragasam, Abirami},
title = {Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.23.00390}
}
EUVIMED